71% of Global Businesses Have Accelerated AI Adoption Amid Tariffs, Inflation and Uncertainty, Finds Economist Study Commissioned by Kinaxis
10.11.2025 13:00:00 CET | Business Wire | Press Release
According to Supply Chain’s Big Bet on AI For Geopolitical Resilience, a new global study from Economist Impact, commissioned by Kinaxis® Inc. (TSX:KXS), while 71% of companies have accelerated AI deployment in response to tariffs, inflation, and geopolitical volatility, a wide gap remains between AI ambition and implementation, according to Economist Impact.
Nearly every company (97%) is experimenting with AI, but only 20% can make real-time decisions, and just 22% have a defined AI strategy, and those with one are more than three times as likely to see measurable ROI. Moreover, while business leaders tend to underestimate the new risks and complexities that AI may introduce, staff are more focused on the practical realities with the effort, change management, and technical challenges involved in turning AI ambition into everyday impact.
“Disruption is no longer cyclical, it’s structural, and AI has become the defining accelerator of adaptability,” said Fab Brasca, Senior Vice President, Market Strategy and Product Management at Kinaxis. “In a world of constant geopolitical and economic turbulence, companies cannot afford to experiment in isolation or chase hype. Those that orchestrate intelligence across the enterprise, by turning data into continuous decisions, will convert volatility into advantage.”
Adoption Is Up, But Action Lags
AI adoption varies widely by use case, revealing where companies are focusing their early efforts - and where critical blind spots remain.
- 52% of organizations report full integration for predictive analytics (the leading use case)
- Fewer than 15% of companies use AI for supplier monitoring, anomaly detection, or geopolitical tracking, the very risks now driving adoption.
At the same time, economic pressure is amplifying the urgency to act as companies face rising costs and supply instability.
- 79% of companies have already passed higher costs on to consumers
- More than three-quarters report worsening availability of key components
Inside organizations, a confidence gap is emerging between leadership optimism and day-to-day execution.
- Two-thirds of C-suite executives expect AI to deliver returns within 12 months
- Less than 50% of junior leaders share that view
Regional Contrasts Are Clear
- Executives in Asia-Pacific (81%) and Europe (78%) report faster AI acceleration than those in North America (57%)
- Executives in Europe (38%) and Asia-Pacific (31%) report stronger AI investment momentum than those in North America (22%), reflecting differences in regulatory environments and risk appetite
- Even in the fastest-moving regions, adoption remains shallow - just 11% use AI for scenario modeling and only 3% for geopolitical tracking.
The Blind Spot - Readiness and Governance
Fewer than one in four business leaders expect AI-related risks to increase over the next three years, revealing a major gap between confidence and capability. While companies are rapidly deploying AI to manage geopolitical and economic shocks, most are not addressing the underlying challenges of data readiness, governance, and accountability that will determine whether those investments pay off.
“The data reveal how far ambition has outpaced readiness,” said Oliver Sawbridge, senior manager, trade, and geopolitics at the Economist. “Companies are racing to deploy AI to manage geopolitical and economic shocks, but most lack the data, systems, and strategies to make it work in real time. It is a reminder that resilience depends as much on preparedness as on innovation.”
This growing disconnect highlights a key theme across the study: as AI moves from experimentation to execution, the ability to govern and scale it responsibly will define who turns adoption into advantage.
The Kinaxis View: From Automation to Adaptation in the new Agentic Age
Fewer than one in ten organizations have begun exploring agentic AI. That is where Kinaxis sees the next frontier - using AI as a foundation for adaptability, where agents and humans orchestrate together, continuously, safely, and in context. Powered by concurrency and governance guardrails, every recommendation is explainable, every action auditable, and every decision aligned to business outcomes.
The findings from Supply Chain’s Big Bet on AI For Geopolitical Resilience reinforce this vision. Real resilience is not automation for efficiency’s sake, it is intelligent adaptation. It is the difference between AI that reacts to disruption and AI that helps organizations stay ahead of it: a future built on agentic orchestration, where planning and execution move together to turn volatility into foresight and adaptability into growth.
Learn more
Download and read the full report here:www.kinaxis.com/en/economist-ai
Register for the live webinar with Kinaxis and Economist Impact on November 20 at 11 a.m. ET.
About the Study
The report is based on a survey of more than 800 senior business leaders across Europe, North America, and Asia-Pacific. Economist Impact conducted the research independently, with sponsorship from Kinaxis.
About Kinaxis
Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
Source: Kinaxis Inc
View source version on businesswire.com: https://www.businesswire.com/news/home/20251110649522/en/
Contacts
Media Relations
Matt Tatham | Kinaxis
mtatham@kinaxis.com
+1 917-446-7227
Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
+1 613-907-7613
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom